Table 1 Between-reader OPA by biomarker

From: Whole tumor section quantitative image analysis maximizes between-pathologists’ reproducibility for clinical immunohistochemistry-based biomarkers

Biomarker

MR

DR

FOV IA

WT IA

 

n/N

OPA (95% CI)

n/N

OPA (95% CI)

n/N

OPA (95% CI)

n/N

OPA (95% CI)

HER2

312/358

87.2 (82.1, 91.9)

324/356

91.0 (86.6, 94.9)

334/356

93.8 (90.0, 97.2)

126/126

100 (97.0, 100)

Ki-67

297/347

85.6 (80.4, 90.4)

268/350

76.6 (70.9, 82.2)

302/348

86.8 (82.1, 91.4)

120/120

100 (96.9, 100)

Estrogen receptor

334/352

94.9 (91.4, 97.8)

309/336

92.0 (87.8, 95.8)

327/343

95.3 (92.0, 98.2)

118/120

98.3 (94.1, 99.5)

Progesterone receptor

334/354

94.4 (90.9, 97.2)

314/334

94.0 (90.2, 97.1)

317/337

94.1 (90.3, 97.2)

113/117

96.6 (91.5, 98.7)

p53

277/355

78.0 (72.2, 83.3)

286/355

80.6 (75.0, 86.0)

290/355

81.7 (76.4, 86.8)

NA

NA

  1. Abbreviations: CI, confidence interval; DR, digital read; FOV, field-of-view; IA, image analysis; MR, manual read; n, number of evaluable cases given the same diagnosis by readers; N, total number of cases evaluated by reader and assigned valid diagnoses for comparison; OPA, overall percent agreement; WT, whole tumor.
Back to article page